scholarly journals Hip fractures following denosumab discontinuation: three clinical cases reports

2019 ◽  
Vol 112 (11) ◽  
pp. 472-475 ◽  
Author(s):  
Manuel Sosa Henríquez ◽  
María Jesús Gómez de Tejada Romero ◽  
María Escudero-Socorro ◽  
Oscar Torregrosa Suau
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Vertebral Fractures ◽  
Femoral Fractures ◽  
Significant Loss ◽  
Mineral Density ◽  
Denosumab Treatment ◽  
Multiple Vertebral Fractures ◽  
Clinical Cases

Summary A significant loss of bone mineral density and the appearance of multiple vertebral fractures after discontinuation of denosumab treatment have been described. To date, no hip fractures have been reported. We present three cases of patients who suffered femoral fractures after denosumab suppression.

The effect of teriparatide on bone mineral density in a woman with severe lactation-related osteoporosis and multiple vertebral fractures

2019 ◽  
Author(s):  
Panagiotis Anagnostis ◽  
Nifon Gkekas ◽  
Eustathios Kenanidis ◽  
Michael Potoupnis ◽  
Eleftherios Tsiridis ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Vertebral Fractures ◽  
Mineral Density ◽  
Multiple Vertebral Fractures

Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis

2020 ◽  
Vol 107 (6) ◽  
pp. 559-566
Author(s):  
Naoki Okubo ◽  
Shigeyuki Matsui ◽  
Toshio Matsumoto ◽  
Toshitsugu Sugimoto ◽  
Takayuki Hosoi ◽  
...  
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Vertebral Fractures ◽  
Mineral Density ◽  
Denosumab Treatment

scholarly journals Should denosumab treatment for osteoporosis be continued indefinitely?

2021 ◽  
Vol 12 ◽  
pp. 204201882110100
Author(s):  
Jane A. Noble ◽  
Malachi J. McKenna ◽  
Rachel K. Crowley
Keyword(s):  
Bone Mineral Density ◽  
Bone Mineral ◽  
Fracture Prevention ◽  
Mineral Density ◽  
Major Osteoporotic Fracture ◽  
Osteoporosis Therapy ◽  
Increased Risk ◽  
Turnover Markers ◽  
Denosumab Treatment ◽  
Multiple Vertebral Fractures

Denosumab was approved for the treatment of postmenopausal osteoporosis in 2010, based on the FREEDOM study, which indicated a benefit in terms of increased bone mineral density and reduced risk of major osteoporotic fracture. In the initial clinical studies it was noted that discontinuation of denosumab can lead to a rebound of bone turnover markers and loss of accrued bone mineral density. An increased risk of fractures (multiple vertebral fractures in particular) associated with discontinuation was noted after approval and marketing of denosumab. For many patients experiencing gain in bone mineral density and fracture prevention while taking denosumab, there is no reason to stop therapy. However, discontinuation of denosumab may happen due to non-adherence; potential lack of efficacy in an individual; where reimbursement for therapy is limited to those with bone mineral density in the osteoporosis range, when assessment reveals this has been exceeded; or patient or physician concern regarding side effects. This review paper aims to discuss these concerns and to summarize the data available to date regarding sequential osteoporosis therapy following denosumab cessation to reduce the risk of multiple vertebral fracture.

The Clinical Use of Denosumab for the Management of Low Bone Mineral Density in Postmenopausal Women

2012 ◽  
Vol 25 (3) ◽  
pp. 310-318 ◽  
Author(s):  
Kira B. Harris ◽  
Kimberly L. Nealy ◽  
Delilah J. Jackson ◽  
Phillip L. Thornton
Keyword(s):  
Bone Mineral Density ◽  
Postmenopausal Women ◽  
Bone Mineral ◽  
Hip Fractures ◽  
Nuclear Factor Κb ◽  
Bisphosphonate Therapy ◽  
Mineral Density ◽  
Osteoporosis Therapy ◽  
Cost Of Health Care ◽  
Therapy Studies

Osteoporosis is a leading cause of debility and declining quality of life in postmenopausal women worldwide. Treatment of osteoporosis has been ubiquitous throughout the developed world since the mid-1990s, most notably with the introduction of bisphosphonates in 1995. Nonetheless, the incidence of hip fractures increased by 25% between 1990 and 2000, despite advances in osteoporosis therapy. Studies indicate that bone density increases over the first 3 years of bisphosphonate therapy and then plateaus or perhaps even declines, placing these patients at greater risk of fracture. Since hip fractures are associated with increased morbidity, mortality, and increased cost of health care, improvements in treating osteoporosis are critical. Denosumab is a novel monoclonal antibody targeted against the receptor activator of nuclear factor-κB ligand (RANKL) that inhibits osteoclast activity. Initial data suggest that denosumab increases bone mineral density for greater than 3 years. Of greater importance, denosumab has been shown to decrease vertebral fractures by 68%, nonvertebral fractures by 19%, and hip fractures by 42% for at least 36 months. Data also indicate that the safety profile of denosumab is equivalent to other drugs used in osteoporosis management, but potential risks of immunosuppression and cancer have been hypothesized.

scholarly journals Prevalence and risk factors of low bone mineral density in spondyloarthritis and prevalence of vertebral fractures

2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Sandrine Malochet-Guinamand ◽  
Bruno Pereira ◽  
Zuzana Tatar ◽  
Anne Tournadre ◽  
Anna Moltó ◽  
...  
Keyword(s):  
Risk Factors ◽  
Bone Mineral Density ◽  
Bone Mineral ◽  
Vertebral Fractures ◽  
Mineral Density ◽  
Low Bone Mineral Density
Sign in / Sign up

Export Citation Format

Share Document